MCID: PDT001
MIFTS: 33

Pediatric Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Pediatric Lymphoma

MalaCards integrated aliases for Pediatric Lymphoma:

Name: Pediatric Lymphoma 12 15
Childhood Lymphoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:5823
NCIt 49 C5165
UMLS 71 C1332979

Summaries for Pediatric Lymphoma

MalaCards based summary : Pediatric Lymphoma, also known as childhood lymphoma, is related to hodgkin's lymphoma, lymphocytic-histiocytic predominance and lymphoma, hodgkin, classic. An important gene associated with Pediatric Lymphoma is MIR582 (MicroRNA 582), and among its related pathways/superpathways are NF-kappaB Signaling and B cell receptor signaling pathway (KEGG). The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Related Diseases for Pediatric Lymphoma

Diseases related to Pediatric Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 133)
# Related Disease Score Top Affiliating Genes
1 hodgkin's lymphoma, lymphocytic-histiocytic predominance 30.3 TNFRSF8 BCL6
2 lymphoma, hodgkin, classic 29.8 TNFRSF8 IRF4 BCL6 ALK
3 alk-positive anaplastic large cell lymphoma 29.7 TNFRSF8 NPM1 ALK
4 lymphoblastic lymphoma 29.6 TNFRSF8 MYC MME BCL6
5 anaplastic large cell lymphoma 29.4 TNFRSF8 NPM1 IRF4 ALK
6 bone lymphoma 29.1 TNFRSF8 MME CD79A BCL6
7 lymphosarcoma 29.0 TNFRSF8 CD22 BCL6
8 peripheral t-cell lymphoma 28.7 TNFRSF8 TCL1A MME BCL6 ALK
9 lung lymphoma 28.4 TNFRSF8 MME IRF4 CD79A BCL6
10 lymphoma 28.4 TNFRSF8 TCL1A NPM1 MYC MME IRF4
11 leukemia, acute lymphoblastic 27.9 MME IRF4 DAPK1 CD22 BCL6
12 burkitt lymphoma 27.4 TNFRSF8 TCL1A MYC MME IRF4 CD22
13 diffuse large b-cell lymphoma 27.4 TNFRSF8 TCL1A MYC MME IRF4 CD79A
14 adult lymphoma 27.1 TNFRSF8 MYC MME IRF4 CD22 BCL6
15 b-cell lymphoma 26.5 TNFRSF8 TCL1A NPM1 MYC MME IRF4
16 lymphoma, non-hodgkin, familial 26.0 TNFRSF8 TCL1A NPM1 MYC MME IRF4
17 systemic epstein-barr virus-positive t-cell lymphoma of childhood 11.3
18 breast lipoma 10.4 TNFRSF8 ALK
19 nodular lymphocyte predominant hodgkin lymphoma 10.4 TNFRSF8 BCL6
20 ureteral lymphoma 10.3 MME BCL6
21 pleural lipoma 10.3 TNFRSF8 ALK
22 inflammatory liposarcoma 10.3 MME ALK
23 ovarian lymphoma 10.3 MME BCL6
24 intravascular large b-cell lymphoma 10.3 MME BCL6
25 t-cell lymphoma, subcutaneous panniculitis-like 10.3 TNFRSF8 ALK
26 small intestine lymphoma 10.3 CD79A BCL6
27 hilar lung carcinoma 10.3 MME CD79A
28 lung hilum cancer 10.3 MME CD79A
29 mediastinal malignant lymphoma 10.2 TNFRSF8 CD79A
30 infected hydrocele 10.2 TNFRSF8 CD79A
31 mediastinal gray zone lymphoma 10.2 TNFRSF8 CD79A
32 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.2 MYC BCL6
33 hodgkin's lymphoma, mixed cellularity 10.2 TNFRSF8 CD79A
34 cerebral lymphoma 10.2 TNFRSF8 CD79A
35 sclerosing hepatic carcinoma 10.2 MME CD79A
36 lymphomatoid papulosis 10.2 TNFRSF8 NPM1 ALK
37 central epithelioid sarcoma 10.2 TNFRSF8 MME
38 autoimmune lymphoproliferative syndrome, type v 10.2 TNFRSF8 BCL6 ALK
39 heart lymphoma 10.2 MME BCL6 ALK
40 vulvar proximal-type epithelioid sarcoma 10.2 TNFRSF8 MME
41 mediastinal cancer 10.2 TNFRSF8 CD79A
42 mesenchymal cell neoplasm 10.2 NPM1 MME ALK
43 plasmablastic lymphoma 10.1 MYC BCL6
44 lung acinar adenocarcinoma 10.1 MYC ALK
45 t-cell/histiocyte rich large b cell lymphoma 10.1 TNFRSF8 MME BCL6
46 alk-negative anaplastic large cell lymphoma 10.1 MYC ALK
47 appendix lymphoma 10.1 TNFRSF8 IGHV4-38-2
48 primary mediastinal large b-cell lymphoma 10.1 IRF4 BCL6
49 angioimmunoblastic t-cell lymphoma 10.1 TNFRSF8 MME BCL6
50 bladder lateral wall cancer 10.1 MYC MME

Graphical network of the top 20 diseases related to Pediatric Lymphoma:



Diseases related to Pediatric Lymphoma

Symptoms & Phenotypes for Pediatric Lymphoma

Drugs & Therapeutics for Pediatric Lymphoma

Drugs for Pediatric Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
2
leucovorin Approved Phase 3 58-05-9 6006 143
3
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
4
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
5
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
6
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
10
Daunorubicin Approved Phase 3 20830-81-3 30323
11
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
12
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
13
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
14
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
15
Mercaptopurine Approved Phase 3 50-44-2 667490
16
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
17
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
18 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
19
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
20
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
21
Thioguanine Approved Phase 3 154-42-7 2723601
22
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
23
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
24
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
25
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
26 Anti-Infective Agents Phase 3
27 Antiviral Agents Phase 3
28 Antirheumatic Agents Phase 3
29 Antimetabolites Phase 3
30
Liposomal doxorubicin Phase 3 31703
31 Immunosuppressive Agents Phase 3
32 Etoposide phosphate Phase 3
33 Immunologic Factors Phase 3
34 Antiemetics Phase 3
35 HIV Protease Inhibitors Phase 3
36 Alkylating Agents Phase 3
37
protease inhibitors Phase 3
38 Gastrointestinal Agents Phase 3
39 Anti-Inflammatory Agents Phase 3
40 Autonomic Agents Phase 3
41 Hormone Antagonists Phase 3
42 Topoisomerase Inhibitors Phase 3
43 BB 1101 Phase 3
44 Antineoplastic Agents, Hormonal Phase 3
45 glucocorticoids Phase 3
46 Hormones Phase 3
47 Anti-Bacterial Agents Phase 3
48 Antibiotics, Antitubercular Phase 3
49 Antimitotic Agents Phase 3
50 Hydrocortisone hemisuccinate Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
2 A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma Completed NCT01492088 Phase 1, Phase 2 Brentuximab vedotin
3 Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma Recruiting NCT01859819 Phase 2 Rituximab;IT Cytarabine
4 An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma Active, not recruiting NCT02979522 Phase 1, Phase 2 Brentuximab vedotin;Doxorubicin;Vinblastine;Dacarbazine
5 A Phase I Trial of Bendamustine in Combination With Clofarabine and Etoposide in Pediatric Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT01900509 Phase 1 Bendamustine;Clofarabine;Etoposide;Etoposide phosphate;Dexamethasone
6 Pilot Study Evaluating the Use of Proton Radiation for Treatment of Lymphoma Involving the Mediastinum Terminated NCT01751412

Search NIH Clinical Center for Pediatric Lymphoma

Genetic Tests for Pediatric Lymphoma

Anatomical Context for Pediatric Lymphoma

MalaCards organs/tissues related to Pediatric Lymphoma:

40
B Cells, T Cells, Bone, Lung, Breast, Bone Marrow, Heart

Publications for Pediatric Lymphoma

Articles related to Pediatric Lymphoma:

(show top 50) (show all 178)
# Title Authors PMID Year
1
Clinicopathological Characterization of Children With B-Cell Non-Hodgkin Lymphoma Over 10 Years at a Tertiary Center in Cape Town, South Africa. 61
31895217 2019
2
Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. 61
31620854 2019
3
Surveillance imaging in pediatric lymphoma. 61
31620855 2019
4
Expanding the phenotype of the X-linked BCOR microphthalmia syndromes. 61
29974297 2019
5
Is True Whole-Body 18F-FDG PET/CT Required in Pediatric Lymphoma? An IAEA Multicenter Prospective Study. 61
30683766 2019
6
Abdominal Lymphoma Presenting as Terminal Ileitis: A Case Report. 61
31003819 2019
7
Case-control study of paternal occupational exposures and childhood lymphoma in Great Britain, 1962-2010. 61
31105271 2019
8
Improving the Brain Delivery of Chemotherapeutic Drugs in Childhood Brain Tumors. 61
31200562 2019
9
Late-onset cardiomyopathy among survivors of childhood lymphoma treated with anthracyclines: a systematic review. 61
30273645 2019
10
Increased 18F-FDG accumulation in the tonsils after chemotherapy for pediatric lymphoma: a common physiological phenomenon. 61
30689118 2019
11
A strong spatial association between e-waste burn sites and childhood lymphoma in the West Bank, Palestine. 61
30259977 2019
12
Two-year-old female with EBV-positive diffuse large B-cell lymphoma and subsequent CNS involvement with neurolymphomatosis. 61
30151967 2018
13
Predictive Value of FDG PET/CT Versus Bone Marrow Biopsy in Pediatric Lymphoma. 61
30358625 2018
14
Translation, psychometric validation, and baseline results of the Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric measures to assess health-related quality of life of patients with pediatric lymphoma in Malawi. 61
30015407 2018
15
Duodenocolonic Fistula As A Rare Complication of Intestinal Burkitt Lymphoma in a Three-Year-Old Boy. 61
29618138 2018
16
Spatial clustering of childhood cancers in Switzerland: a nationwide study. 61
29442212 2018
17
Pharmacotherapeutic Management of Pediatric Lymphoma. 61
29127674 2018
18
Inhibitory Effect of Fruit Juices on the Doxorubicin Metabolizing Activity of Carbonyl Reductase 1. 61
28332451 2017
19
Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI. 61
28534182 2017
20
Pediatric Lymphoma. 61
28864732 2017
21
Adverse Health Outcomes and Associations with Self-Reported General Health in Childhood Lymphoma Survivors. 61
28837384 2017
22
Experiences with late effects-related care and preferences for long-term follow-up care among adult survivors of childhood lymphoma. 61
28236146 2017
23
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). 61
28379322 2017
24
Quantifying bias in survival estimates resulting from loss to follow-up among children with lymphoma in Malawi. 61
27896944 2017
25
Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A population-based case-control study. 61
27896915 2017
26
Erratum to: Role of PET/CT in malignant pediatric lymphoma. 61
28058463 2017
27
Comparison of 11C-Methionine and 18F-FDG PET/CT for Staging and Follow-up of Pediatric Lymphoma. 61
27609791 2017
28
Recent progress in the treatment of pediatric lymphoma in Japan. 61
28978862 2017
29
Beyond Endemic Burkitt Lymphoma: Navigating Challenges of Differentiating Childhood Lymphoma Diagnoses Amid Limitations in Pathology Resources in Lilongwe, Malawi. 61
28680947 2017
30
Utility of Global Longitudinal Strain by Echocardiography to Detect Left Ventricular Dysfunction in Long-Term Adult Survivors of Childhood Lymphoma and Acute Lymphoblastic Leukemia. 61
27296561 2016
31
Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma. 61
27003132 2016
32
[Childhood nasal lymphoma:two cases report and literature review]. 61
29797985 2016
33
Right ventricular function in long-term adult survivors of childhood lymphoma and acute lymphoblastic leukaemia. 61
26917232 2016
34
Imaging of primary pediatric lymphoma of bone. 61
27043729 2016
35
Relationship and interactions of curcumin with radiation therapy. 61
27298767 2016
36
Socioeconomic Factors Impact Inpatient Mortality in Pediatric Lymphoma Patients. 61
27433403 2016
37
Assessment of Sequential PET/MRI in Comparison With PET/CT of Pediatric Lymphoma: A Prospective Study. 61
26901021 2016
38
Epstein-Barr Virus-Positive T/NK-Cell Lymphoproliferative Disorders Manifested as Gastrointestinal Perforations and Skin Lesions: A Case Report. 61
26844502 2016
39
Emerging immunotherapy in pediatric lymphoma. 61
26616565 2016
40
Antibody therapies for lymphoma in children. 61
26784573 2016
41
Childhood lymphoma. 61
27795541 2016
42
A Pilot Study of 18F-FLT PET/CT in Pediatric Lymphoma. 61
27313888 2016
43
Prevalence and clinical manifestation of lymphomas in North Eastern Nigeria. 61
26960474 2015
44
Residential Radon Exposure and Incidence of Childhood Lymphoma in Texas, 1995-2011. 61
26404336 2015
45
Treatment of pediatric lymphoma in Japan: Current status and plans for the future. 61
26096060 2015
46
Childhood lymphoma incidence patterns by ICCC-3 subtype in Mexico City metropolitan area population insured by Instituto Mexicano del Seguro Social, 1996-2010. 61
25779380 2015
47
Bilateral ovarian B-lineage lymphoblastic lymphoma with MLL gene rearrangement: a novel case in infancy. 61
25493458 2015
48
Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19-20 September 2014. 61
26086968 2015
49
Occupational exposure to pentachlorophenol causing lymphoma and hematopoietic malignancy for two generations. 61
23315091 2015
50
Impact of cancer support groups on childhood cancer treatment and abandonment in a private pediatric oncology centre. 61
25709189 2015

Variations for Pediatric Lymphoma

Expression for Pediatric Lymphoma

Search GEO for disease gene expression data for Pediatric Lymphoma.

Pathways for Pediatric Lymphoma

GO Terms for Pediatric Lymphoma

Biological processes related to Pediatric Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.02 TCL1A NPM1 MYC DAPK1 BCL6
2 B cell activation GO:0042113 8.96 CD79A CD22

Molecular functions related to Pediatric Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 core promoter binding GO:0001047 8.62 NPM1 MYC

Sources for Pediatric Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....